Teva Pharmaceutical Industries Limited
TEVJF
$29.19
$0.832.93%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.41% | 4.32% | 0.02% | 2.07% | 3.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.41% | 4.32% | 0.02% | 2.07% | 3.82% |
| Cost of Revenue | -1.53% | -1.89% | -0.46% | 1.85% | 3.38% |
| Gross Profit | 10.55% | 10.84% | 0.51% | 2.31% | 4.29% |
| SG&A Expenses | 8.52% | 7.30% | 4.16% | 5.12% | 5.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -312.50% | 90.91% | 5.00% | 27.27% | 166.67% |
| Total Operating Expenses | 1.14% | 1.03% | 1.00% | 2.54% | 4.18% |
| Operating Income | 17.02% | 17.12% | -3.40% | 0.37% | 2.48% |
| Income Before Tax | 365.51% | 196.26% | 269.94% | 51.05% | 36.78% |
| Income Tax Expenses | -123.35% | -126.67% | -65.41% | -84.68% | 2,153.85% |
| Earnings from Continuing Operations | 218.56% | 172.28% | 154.31% | 78.27% | -68.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -102.94% | -102.19% | -80.23% | -98.32% | -88.78% |
| Net Income | 221.62% | 185.97% | 174.24% | 65.12% | -168.48% |
| EBIT | 17.02% | 17.12% | -3.40% | 0.37% | 2.48% |
| EBITDA | 12.37% | 11.79% | -3.55% | -0.96% | -0.16% |
| EPS Basic | 219.76% | 184.91% | 173.52% | 63.80% | -165.52% |
| Normalized Basic EPS | 21.04% | 2.51% | -13.18% | -14.64% | -10.10% |
| EPS Diluted | 215.38% | 182.36% | 169.57% | 60.64% | -161.53% |
| Normalized Diluted EPS | 19.39% | 0.80% | -13.69% | -14.62% | -9.76% |
| Average Basic Shares Outstanding | 1.37% | 1.30% | 1.22% | 1.18% | 1.16% |
| Average Diluted Shares Outstanding | 2.61% | 2.99% | 2.01% | 1.28% | 0.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |